glp 1 therapy for diabetes WHO Endorses GLP‑1 Obesity Care: Implications Providers Practice Nursing - GLP-1 receptor
Description
GLP-1 receptor agonist Weve already seen a shift in how food companies market their products
Federally, yes the DEA extended COVID-era waivers allowing controlled substance prescribing via telehealth through December 31, 2025
Multivariate analysis of 12-month HbA1c reported that HbA1c significantly increased after cessation of liraglutide in the liraglutide group by ~10.9 mmol/mol when compared to placebo (10.9 mmol/mol, 95%CI: 1.1, 20.6 mmol/mol, p = 0.032, Supplementary Table 5.4)
There were moments of stability and hope, but the journey was also marked by setbacks
